- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05289648
Niraparib in High-grade Endometrial Cancer Trial (NIREC)
The Molecular and the Clinical Effects of Preoperative Niraparib in Patients With High-grade Endometrial Cancer: Phase 0 Exploratory Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Shannon Salvador, MD MSc
- Phone Number: 23114 +15143408222
- Email: shannon.salvador@mcgill.ca
Study Contact Backup
- Name: David Knigin, MD PhD
- Phone Number: 22797 +15143408222
- Email: david.knigin@mail.mcgill.ca
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients must be female ≥18 years of age, able to understand the study procedures and agree to participate in the study by providing written informed consent
Histological and staging criteria:
Patients must have histologically diagnosed
- Grade 3 endometrioid, serous or clear cell endometrial carcinoma, carcinosarcoma, undifferentiated carcinoma in Stage I-III according to International Federation of Gynecology and Obstetrics (FIGO) classification.
- Grade 2 endometrioid carcinoma with abnormal TP53 by immunohistochemistry.
- Surgical criteria: patients with operable disease are eligible
- Patients of childbearing potential must have a negative serum pregnancy test (beta human chorionic gonadotropin [hCG]) within 7 days prior to receiving the first dose of niraparib.
- Patients must be postmenopausal, free from menses for >1 year, surgically sterilized, or willing to use adequate contraception to prevent pregnancy or must agree to abstain from activities that could result in pregnancy throughout the study, starting with enrollment through 3 months after the last dose of niraparib.
- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Patients must have adequate organ function, defined as follows:
- Absolute neutrophil count ≥ 1,500/µL
- Platelets ≥ 100,000/µL
- Hemoglobin ≥ 10 g/dL
- Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or calculated creatinine clearance ≥ 60 mL/min using the Cockcroft-Gault equation
- Total bilirubin ≤ 1.5 x ULN
- Aspartate aminotransferase and alanine aminotransferase ≤ 2.0 x ULN
- Patients must be able to take oral medications
Exclusion Criteria:
Histology:
- Grade 1 endometrioid carcinoma OR
- Grade 2 endometrioid carcinoma with wild type TP53 OR
- Grade 2 endometrioid carcinoma with an unknown TP53 status
Patient did not consent for the study biopsy and one of the following:
- the original endometrial biopsy tissue block could not be assessed by the study site pathologist
- the original endometrial biopsy tissue block does not contain sufficient tumor tissue
- Patient is pregnant, breastfeeding, or expecting to conceive children, while receiving study treatment and for 3 months after the last dose of study treatment;
- Patient has a known hypersensitivity to the components of niraparib or its excipients;
- Patient is simultaneously enrolled in any clinical trial of niraparib or any other investigational therapy;
- Patient has had any known ≥Grade 3 anemia, neutropenia or thrombocytopenia due to any prior medication that persisted >4 weeks;
- Patient has any known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myelocytic anemia (AML);
- Patient has undergone major surgery (per investigator judgment) within 3 weeks of starting the study or patient has not recovered from any effects of any major surgery;
Patient has a condition (such as transfusion dependent anemia or thrombocytopenia), therapy, or laboratory abnormality that might confound the study results or interfere with the patient's participation for the full duration of the study treatment, including:
- Patient received a transfusion (platelets or red blood cells) within 2 weeks of the first dose of study treatment;
- Patient received colony-stimulating factors (eg, granulocyte colony stimulating factor [G-CSF], granulocyte macrophage colony-stimulating factor [GM-CSF] or recombinant erythropoietin) within 2 weeks prior to the first dose of study treatment.
- Another concurrent invasive neoplastic disease (including ovarian), diagnosis of cancer in the last 5 years (except for non-melanoma skin cancer), patient previously had cancer (> 5 years) but she is not considered cured or still treated.
Patient is considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease, or active, uncontrolled infection;
- Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent.
- Patient is immunocompromised (patients with splenectomy are allowed).
- Patient has known, active hepatic disease (ie, hepatitis B or C).
- Patient has a corrected QT interval (QTc) prolongation > 470 milliseconds at screening; - If a patient has a prolonged QTc interval and the prolongation is deemed to be due to a pacemaker upon investigator evaluation (ie, the patient otherwise has no cardiac abnormalities), then the patient may be eligible to participate in the study following approval of a cardiology specialist.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Preoperative Niraparib
Single arm.
Following the initial assessment and endometrial biopsy the participants will receive niraparib for 28 days.
After the treatment period the patients will be surgically staged.
All participants will receive the standard of care.
|
Low dose oral niraparib capsules (2 x 100 mg) once a day for 28 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor cells proliferation before and after the treatment
Time Frame: Day 30 (day of surgery)
|
Cancer cell proliferation will be quantitatively assessed using immunohistochemical staining for cell-cycle proteins. Ki-67 (MIB) stains nuclei of cells in G1-S-G2 phases of the cell-cycle. The proliferation index will be calculated as percent of tumor positive cells. The primary outcome fold change in proliferation index after exposure to niraparib. The quantification will be done by image analysis software with pathologist supervision. |
Day 30 (day of surgery)
|
Cell cycle arrest
Time Frame: Day 30 (day of surgery)
|
The levels of different cell-cycle related proteins increase and decrease throughout the cell cycle, each having its own expression pattern. Tumor specimens will be stained for Cyclin D1, Geminin and p21 proteins. The proportion of positive nuclei of each marker after exposure to niraparib will be estimated. The results will be integrated to study the effect of niraparib on endometrial cancer cells proliferation. |
Day 30 (day of surgery)
|
Apoptosis marker
Time Frame: Day 30 (day of surgery)
|
Cleaved caspase-3 (cCas-3) marks cells that activated the programmed cell-death process.
cCas-3 positive tumor cells will be compared before and after the exposure to niraparib.
|
Day 30 (day of surgery)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Endometrial thickness
Time Frame: Day 1 and Day 28
|
Comparison of the thickness of endometrial lining before and after treatment
|
Day 1 and Day 28
|
CA-125 cancer tumor marker
Time Frame: Day 1 and Day 28
|
Investigation of the effect of preoperative niraparib on CA125 levels in patients with high grade endometrial carcinoma
|
Day 1 and Day 28
|
Adverse effects of Niraparib
Time Frame: every week from day 1 and 21 days after the surgery
|
Assessment of adverse effects of niraparib in chemotherapy naïve patients according to CTCAE 5.0
|
every week from day 1 and 21 days after the surgery
|
Patient Reported Outcomes - General Oncology
Time Frame: Day 1 and Day 28
|
Patients' well being will be assessed by a validated questionnaire: Functional Assessment of Cancer Therapy - General (FACT-G).
https://www.facit.org
|
Day 1 and Day 28
|
Patient Reported Outcomes - Endometrial Cancer
Time Frame: Day 1 and Day 28
|
Patients' well being will be assessed by a validated questionnaire: Functional Assessment of Cancer Therapy - Endometrial (FACT-en).
https://www.facit.org
|
Day 1 and Day 28
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Alternation in genes expression
Time Frame: Day 30 (day of surgery)
|
Gene expression profile by RNA sequencing extracted from snap-frozen tumor tissue.
Unsupervised hierarchical clustering of 2-fold changed genes will be used to detect the pathways affected by niraparib treatment.
|
Day 30 (day of surgery)
|
Genomic analysis
Time Frame: Day 30 (day of surgery)
|
Mutational signature and the altered genes of the DNA repair pathway will be identified by DNA next generation sequencing.
Genomic findings will be correlated with molecular analysis for discovery of biomarkers for niraparib sensitivity in chemotherapy-naïve endometrial cells.
|
Day 30 (day of surgery)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Shannon Salvador, MD MSc, McGill University, Jewish General Hospital
- Principal Investigator: Walter Gotlieb, MD PhD, McGill University, Jewish General Hospital
Publications and helpful links
General Publications
- Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Madry R, Christensen RD, Berek JS, Dorum A, Tinker AV, du Bois A, Gonzalez-Martin A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA; ENGOT-OV16/NOVA Investigators. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016 Dec 1;375(22):2154-2164. doi: 10.1056/NEJMoa1611310. Epub 2016 Oct 7.
- de Jonge MM, Auguste A, van Wijk LM, Schouten PC, Meijers M, Ter Haar NT, Smit VTHBM, Nout RA, Glaire MA, Church DN, Vrieling H, Job B, Boursin Y, de Kroon CD, Rouleau E, Leary A, Vreeswijk MPG, Bosse T. Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas. Clin Cancer Res. 2019 Feb 1;25(3):1087-1097. doi: 10.1158/1078-0432.CCR-18-1443. Epub 2018 Nov 9.
- Urick ME, Bell DW. Clinical actionability of molecular targets in endometrial cancer. Nat Rev Cancer. 2019 Sep;19(9):510-521. doi: 10.1038/s41568-019-0177-x. Epub 2019 Aug 6.
- Romero I, Rubio MJ, Medina M, Matias-Guiu X, Santacana M, Schoenenberger JA, Guerra EM, Cortes A, Minig L, Coronado P, Cueva JF, Gomez L, Malfettone A, Sampayo M, Llombart-Cussac A, Poveda A. An olaparib window-of-opportunity trial in patients with early-stage endometrial carcinoma: POLEN study. Gynecol Oncol. 2020 Dec;159(3):721-731. doi: 10.1016/j.ygyno.2020.09.013. Epub 2020 Sep 26.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Uterine Diseases
- Cystadenocarcinoma
- Neoplasms, Cystic, Mucinous, and Serous
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Endometrial Neoplasms
- Cystadenocarcinoma, Serous
- Uterine Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Poly(ADP-ribose) Polymerase Inhibitors
- Niraparib
Other Study ID Numbers
- 301014
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endometrial Cancer
-
Assistance Publique - Hôpitaux de ParisUniversité Montpellier; Ecole d'econmie de Paris (PSE)-Hospinnomics; Université...CompletedEndometrial Cancer Stage I | Endometrial Cancer Stage IIFrance
-
Radboud University Medical CenterMaastricht University Medical Center; Erasmus Medical Center; Catharina Ziekenhuis... and other collaboratorsRecruitingEndometrial Cancer Recurrent | Endometrial Cancer Stage III | Endometrial Cancer Stage IVNetherlands
-
Batman Training and Research HospitalEskisehir Osmangazi UniversityCompletedGynecologic Cancer | Endometrial Cancer Stage
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingAdvanced Endometrial CancerChina
-
Novartis PharmaceuticalsCompletedAdvanced Endometrial CancerBelgium, France, Italy, Canada, Spain, Australia, Germany, United States, Japan, Brazil, Singapore, Russian Federation, Poland
-
Rambam Health Care CampusCompletedSerous Papillary Endometrial CancerIsrael
-
Samsung Medical CenterRecruitingEndometrial Cancer Stage IKorea, Republic of
-
Duke UniversityDuke Cancer InstituteCompleted
-
Far Eastern Memorial HospitalCompletedOutcome of Endometrial CancerTaiwan
-
University of Southern DenmarkDanish Cancer Society; Region of Southern DenmarkRecruitingEmpowerment, Cervical Cancer, Endometrial Cancer, Follow-up, Nurse-led, PROMDenmark
Clinical Trials on Niraparib oral capsule
-
Institute of Cancer Research, United KingdomRoyal Marsden NHS Foundation TrustNot yet recruitingOvarian Cancer RecurrentUnited Kingdom
-
Tesaro, Inc.Completed
-
Tesaro, Inc.Completed
-
Brigham and Women's HospitalCompleted
-
Aelis FarmaNational Institute on Drug Abuse (NIDA)CompletedHealthy VolunteersUnited States
-
Brigham and Women's HospitalEnrolling by invitation
-
EicOsis Human Health Inc.National Institute of Neurological Disorders and Stroke (NINDS)CompletedHealthy AdultsUnited States
-
Brigham and Women's HospitalCompleted
-
Yale UniversityNeurocrine BiosciencesRecruitingTrichotillomania (Hair-Pulling Disorder)United States
-
Alkermes, Inc.Terminated